UK hospital to develop pioneering radiotherapy

New £9.6m machine will be able to deliver doses of radiation to moving tumoursRelated items from OnMedica£250m investment in proton cancer therapySingle dose radiotherapy for early breast cancer set to become standardBreakthrough for long-term survival in lung cancerGlobal cancer burden set to soarNHS invests £30m in hi tech cancer therapy
Source: OnMedica Latest News - Category: UK Health Source Type: news

Related Links:

AbstractPurposeThis observational study was designed to measure baseline energy parameters and body composition in early-stage breast cancer patients, and to follow changes during and after various modalities of treatment. This will provide information to aid in the development of individualized physical activity intervention strategies.MethodsPatients with newly diagnosed stage 0 –III breast cancer were enrolled into three cohorts: A (local therapy alone), B (endocrine therapy), or C (chemotherapy with or without endocrine therapy). At baseline, 6 months, and 12 months, subjects underwent a stationary bicy...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Source: BMJ Comments - Category: General Medicine Source Type: forums
In conclusion, the synthesized DOX@nanocomposite can be applied in theranostic applications and anticancer drug delivery owing to admissible properties. PMID: 30307331 [PubMed - as supplied by publisher]
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
This article provides an update of data that help inform clinicians of the role anthracyclines should play in adjuvant breast cancer therapy. Two recently reported large randomized trials—the Anthracycline in Early Breast Cancer and Western German Study Plan B studies—compared a taxane and cyclophosphamide regimen with an anthracycline, taxane, and cyclophosphamide regimen. Although the studies had conflicting results, together these studies suggest that the benefit of adjuvant anthracycline therapy over a nonanthracycline taxane‐containing regimen is modest at best and may be primarily seen in patients with ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Review, Breast Cancer Source Type: research
Publication date: 1 January 2019Source: Colloids and Surfaces B: Biointerfaces, Volume 173Author(s): Abhishesh Kumar Mehata, Shreekant Bharti, Priya Singh, Matte Kasi Viswanadh, Lakshmi Kumari, Poornima Agrawal, Sanjay Singh, Biplob Koch, Madaswamy S. MuthuAbstractBreast cancer, up-regulated with human epidermal growth factor receptor type-2 (HER-2) has led to the concept of developing HER-2 targeted anticancer therapeutics. Docetaxel-loaded D-α-tocopherol polyethylene glycol 1000 succinate conjugated chitosan (TPGS-g-chitosan) nanoparticles were prepared with or without Trastuzumab decoration. The particle size and ...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
ConclusionSolely regarding sensitivity of AUS, our study could show significant differences between biological subtypes of breast cancer with lower sensitivity in Luminal patients. While PPV was excellent, standing for a low overtreatment rate using AUS for clinical decision making, sensitivity was poor overall, comparable to the results of other studies.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
This study demonstrates that aptamer-conjugated AuNCs are effective tumor-targeting photothermal agents.Graphical abstractAptamer-incorporated, hollow gold nanoparticles were developed for NIR light-triggered photothermal cancer therapy.
Source: Journal of Industrial and Engineering Chemistry - Category: Chemistry Source Type: research
Condition-specific modules in multiple networks must be determined to reveal the underlying molecular mechanisms of diseases. Current algorithms exhibit limitations such as low accuracy and high sensitivity to the number of networks because these algorithms discover condition-specific modules in multiple networks by separating specificity and modularity of modules. To overcome these limitations, we characterize condition-specific module as a group of genes whose connectivity is strong in the corresponding network and weak in other networks; this strategy can accurately depict the topological structure of condition-specific...
Source: IEEE/ACM Transactions on Computational Biology and Bioinformatics - Category: Bioinformatics Source Type: research
Abstract Stimuli-responsive drug-delivery nanocarriers (DDNs) have been increasingly reported in the literature as an alternative for breast cancer therapy. Stimuli-responsive DDNs are developed with materials that present a drastic change in response to intrinsic/chemical stimuli (pH, redox and enzyme) and extrinsic/physical stimuli (ultrasound, light, magnetic field and electric current). In addition, they can be developed using different strategies, such as functionalization with signaling molecules, leading to several advantages, such as (a) improved pharmaceutical properties of liposoluble drugs, (b) selectiv...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
ConclusionThe considerable concerns on the use of CD and DO in breast cancer patients could be relieved to some extents upon the findings of this pre-clinical study. The potential harmful effects of estrogenic Chinese herbal medicines on breast cancer growth should be verified in both cell-based and tumor-bearing mice models.Graphical abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Hospitals | UK Health